PharmNovo appoints CFO and Clinical Lead to strengthen the organisation
PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, announces that the company has strengthened the team entering the clinical phase. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in a share issue led by Sciety earlier this summer. Tommy Nilsson has a background as CFO at subsidiaries